Xenon paused enrollment in its major depressive disorder and bipolar depression studies after an analysis found neuropsychiatric adverse events. That pause will delay trial data and raises safety and regulatory scrutiny for those programs.
The enrollment pause reduces Xenon's ability to keep testing its depression programs and slows when it can deliver results. The pause follows an analysis that found neuropsychiatric adverse events, which raises safety and regulator attention and hurts investor confidence.
Steel Dynamics provided a new third-quarter EPS view of $5.34-$5.38 per share, higher than recent quarters. That raises expected third-quarter profit versus the second quarter and the year-ago period.
Nucor gave third-quarter earnings guidance of $5.55 to $5.65 per diluted share, higher than the year-ago $2.63. That suggests stronger expected profit this quarter versus last year.
Frontline fell 6.4% to $50.65 in pre-market trading; the story only reports an intraday price move and gives no company news, so it does not change Frontline's outlook.
Biohaven fell 6.4% to $13.00 in pre-market trading after jumping the prior day; the piece reports only price action and no new company information, so the reading unchanged.
Array Technologies declined 4.3% to $4.06 in pre-market trading; the article only notes the price move and provides no company-specific news to change the view.
Follow Xenon Pharmaceuticals Inc (XENE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XENE